ProtecT trial: What's new after 15 years of follow-up: Re: Hamdy FC and colleagues; N Engl J Med. 2023 Apr 27.
Mario TerlizziAlberto BossiPublished in: Urologia (2024)
Recent results of ProtecT trial published after 15 years of follow-up demonstrate the absence of difference in prostate cancer-specific survival between active monitoring, radiotherapy, or prostatectomy for PSA-detected, localized prostate cancer patients. These results definitively confirm the essential role of active surveillance as the gold standard for men with low-risk and highly selected intermediate-risk prostate cancer. It underlines the importance of shared-decision making process with patients.
Keyphrases
- prostate cancer
- radical prostatectomy
- end stage renal disease
- study protocol
- clinical trial
- phase iii
- ejection fraction
- newly diagnosed
- early stage
- phase ii
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- benign prostatic hyperplasia
- squamous cell carcinoma
- middle aged
- radiation induced
- locally advanced